

Information sheet on the storage and transport of abnobaVISCUM

abnobaVISCUM 20mg; 2mg; 0,2mg; 0,02mg:

Our products are regularly inspected for the stability of the ingredients in compliance with the internationally valid ICH Guidelines*.

These inspections take into account cold storage, storage at temperatures of 25°C, 30°C and 40°C and conditions in various climatic zones.

As the manufacturer, we therefore make the following recommendations for storage and transport:

abnobaVISCUM 20mg; 2mg; 0,2mg; 0,02mg:

Storage:	Cold storage at 2–8°C; do not freeze
Transport:	No cold chain distribution requirement!
Transport at 2–25°C:	No product impairment up to 3 weeks
Transport at peak temperatures up to approx. 30°C:	No product impairment up to 1 week
Transport at peak temperatures up to approx. 40°C:	Preferably avoid, but no product impairment up to 24 h

Please do not hesitate to contact us with any queries on Tel.: +49 (0)7233. 7043-200.

Niefern-Öschelbronn, March 2024

ABNOBA GmbH



Axel Groß
(Executive director)



Katja Tubach
(Pharmacist)

*ICH Q1A (CPMP/ICH/2736/99) Guideline of the International Conference on Harmonisation: Stability testing of new drug substances and products

Information sheet on the storage and transport of abnobaVISCUM and Betula Folium D3

abnobaVISCUM D6; D10; D20; D30 and Betula Folium D3:

Our products are regularly inspected for the stability of the ingredients in compliance with the internationally valid ICH Guidelines*.

These inspections take into account cold storage, storage at temperatures of 25°C, 30°C and 40°C and conditions in various climatic zones.

As the manufacturer, we therefore make the following recommendations for storage and transport:

abnobaVISCUM D6; D10; D20; D30 and Betula Folium D3:

Storage:	Storage at room temperature
Transport:	
Transport at 2–25°C:	stable
Transport at peak temperatures up to approx. 30°C:	No product impairment up to 1 week
Transport at peak temperatures up to approx. 40°C:	Preferably avoid, but no product impairment up to 24 h

Please do not hesitate to contact us with any queries on Tel.: +49 (0)7233. 7043-200.

Niefen-Öschelbronn, March 2024

ABNOBA GmbH



Axel Groß
(Executive director)



Katja Tubach
(Pharmacist)

*ICH Q1A (CPMP/ICH/2736/99) Guideline of the International Conference on Harmonisation: Stability testing of new drug substances and products